Vivian Rose, MD
Endocrinology · Coral Springs, FLNPI 1013020072
Payments from drug & device makers
Across 698 payments — averaging $306.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$201K
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$1K
- Novo Nordisk$1K
- AstraZeneca$1K
- Tandem Diabetes Care, Inc.$1K
- plus $5K from 27 others
Across 11 payments — averaging $111.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$1,1008%
- Food & beverage$12,51891%
- Education$440%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $201,372 |
| Lilly USA, LLC | 116 | $2,043 |
| Sanofi-aventis U.S. LLC | 73 | $1,472 |
| Novo Nordisk | 81 | $1,472 |
| AstraZeneca(2 entities) | 50 | $1,198 |
| Tandem Diabetes Care, Inc. | 4 | $1,100 |
| Mannkind Corporation | 43 | $948 |
| Insulet Corporation | 31 | $713 |
| Corcept Therapeutics | 40 | $698 |
| Amgen(2 entities) | 22 | $564 |
| Amneal Pharmaceuticals LLC | 34 | $553 |
| Boehringer Ingelheim | 24 | $478 |
| Merck | 13 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $180 |
| Abbott | 8 | $149 |
| Dexcom, Inc. | 7 | $129 |
| Xeris Pharmaceuticals, Inc. | 6 | $116 |
| Amarin Pharma, Inc. | 1 | $111 |
| Recordati_rare_diseases_inc. | 5 | $92 |
| Neurocrine Biosciences, Inc. | 3 | $75 |
| Bayer | 2 | $60 |
| Johnson & Johnson | 3 | $53 |
| Aytu Biopharma, Inc. | 4 | $52 |
| IBSA Pharma Inc. | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Senseonics, Incorporated | 1 | $25 |
| Lifescan, Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $21 |
| Avvisto Therapeutics, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Vistapharm, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$1,100
- FARXIGA$250
- AFREZZA$125
- TEPEZZA$123
- Vascepa$111
How this compares
Too few endocrinology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 208 | $345,181 |
| JardianceEmpagliflozin | 278 | $299,137 |
| MounjaroTirzepatide | 129 | $187,592 |
| RybelsusSemaglutide | 75 | $138,649 |
| TrulicityDulaglutide | 90 | $117,012 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 79 | $79,006 |
| FarxigaDapagliflozin Propanediol | 79 | $69,310 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 57 | $55,425 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $39,868 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $37,151 |
| JanuviaSitagliptin Phosphate | 41 | $36,689 |
| SynthroidLevothyroxine Sodium | 340 | $35,390 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 69 | $25,163 |
| UnithroidLevothyroxine Sodium | 156 | $19,032 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $18,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,472 | $492,635307 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,043 | $307,842230 claims |
| Boehringer IngelheimJardiance | $478 | $299,137278 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,472 | $80,56992 claims |
| MerckJanumet, Januvia | $245 | $73,84173 claims |
| AstraZenecaFarxiga | $1,198 | $69,31079 claims |
| AbbVieSynthroid | $201,372 | $35,390340 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $553 | $22,779525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Coral Springs
- Rodolfo Perez LopezHialeah$10.6M
- Bryan VinikBoca Raton$13K
- Renee FreedmanBoca Raton$10K
- Rolando RodriguezBoca Raton$8K
- Carlos ZapataTallahassee$5K
- Michael FiliMiami$4K
- Mohammad BaigTampa$2K
- Myat MyintHudson$182
- Kathryn JonesBoca Raton$142
- Alan BalsamDeerfield Beach$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.